BioSpace News Archive

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO

ViewRay, Inc. (Nasdaq: VRAY) (“the Company”) today announced that Shahriar Matin, Chief Operating Officer, will leave the Company effective March 31, 2021.

CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, announces it has been selected by Fierce Medtech as a 2020 “Fierce 15” company, designating it as one of the most promising private medtech companies in the industry.

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced a strategic, exploratory immunotherapy sponsored research agreement with the Johns Hopkins University to study the potential of checkpoint inhibitors combined with RTGel™ in glioblastoma multiforme, or GBM, an aggressive and difficult to treat brain cancer

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its new synthetic RNA reference controls, which include the new variant strains of SARS-CoV-2 B.1.351 and P.1, that have emerged in South Africa and Brazil, respectively

Biotricity, Inc. , a medical diagnostic and consumer healthcare technology company, is pleased to announce that CEO Waqaas Al-Siddiq will present at Maxim Groups Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021.

Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it is working with the U.S. Department of Energy Bioenergy Technologies Office’s Agile BioFoundry (ABF) to generate the largest multi-omics dataset for guiding the development of organic acids.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today reported its financial results for the fourth quarter and full year 2020, and provided a business update.

CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved by the New Jersey Economic Development Authority (NJEDA) to transfer approximately $1.3 million of the total $1.3 million of its available tax benefits to an unrelated,

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announces that Nanox’s Founder and Chief Executive Officer Ran Poliakine will deliver a company presentation and the leadership team will host investor 1x1 meetings during the Oppenheimer 31st Annual Virtual Healthcare Conference